Adam Walsh

Stock Analyst at Roth Capital

(2.72)
# 2,351
Out of 5,182 analysts
18
Total ratings
62.5%
Success rate
19.16%
Average return
Main Sectors:
Top Industries:

Stocks Rated by Adam Walsh

Equillium
Apr 17, 2026
Reiterates: Buy
Price Target: $12
Current: $2.04
Upside: +488.24%
Insmed
Apr 17, 2026
Reiterates: Buy
Price Target: $212
Current: $135.98
Upside: +55.91%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $40.95
Upside: -24.30%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $29.40
Upside: +97.28%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146$171
Current: $226.66
Upside: -24.56%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121$188
Current: $28.55
Upside: +558.49%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $46.22
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74$77
Current: $23.99
Upside: +220.97%